|Title:||Emerging Technologies Director|
|Primary Industry:||Pharma & Biotech|
|Executive Summary:||Arrogene, Inc. was founded by research leaders in the Departments of Neurosurgery and Surgery at Cedars-Sinai Medical Center, where an effective Cancer treatment for Brain and Breast Cancers has been developed. Arrogene has demonstrated both an effective cancer drug and a blockbuster drug delivery platform.
The company has a novel Cancer drug named Polycefin with proven effectiveness and lack of toxicity in vitro and in vivo. Polycefin is a nano-bioconjugate, based on a molecular “scaffold”, poly L-malic acid. Polycefin is non-toxic, non-immunogenic, biodegradable and has demonstrated the ability to carry multiple drugs and monoclonal antibodies simultaneously. Polycefin effectively localizes to and specifically penetrates the vascular system at tumor sites and enters tumor cells inhibiting several specific targets for brain and breast cancer. Polycefin successfully penetrates the blood brain barrier (BBB) and blood tumor barrier (BTB), and is a platform technology that holds the promise of treating other forms of cancer and neurodegenerative disorders.
Arrogene holds a patent portfolio of 6 patents. The company has excellent validation from the National Cancer Institute in receiving an R01 Research Grant with a score in the top 2% percentile. Arrogene is seeking equity capital to continue human clinical trials.